



# SAFETY DATA SHEET

Revision date: 06-Nov-2014

Version: 3.0

Page 1 of 9

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Lincomycin Hydrochloride Capsules

**Trade Name:** Lincocin®; LINCOCINE

**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as antibiotic agent

### Details of the Supplier of the Safety Data Sheet

Pfizer Inc

Pfizer Pharmaceuticals Group

235 East 42nd Street

New York, New York 10017

1-800-879-3477

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd,

Kent

CT13 9NJ

United Kingdom

+00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Skin Sensitization: Category 1

#### EU Classification:

EU Indication of danger: Xi - Irritant

EU Risk Phrases:

R43 - May cause sensitization by skin contact.

### Label Elements

**Signal Word:** Warning

**Hazard Statements:** H317 - May cause an allergic skin reaction

#### Precautionary Statements:

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray

P272 - Contaminated work clothing should not be allowed out of the workplace

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P302+ P352 - IF ON SKIN: Wash with plenty of soap and water

P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention

## SAFETY DATA SHEET

Material Name: Lincomycin Hydrochloride Capsules  
Revision date: 06-Nov-2014

Page 2 of 9  
Version: 3.0



**Other Hazards**  
**Australian Hazard Classification (NOHSC):**

No data available  
Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

**Hazardous**

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Lincomycin Hydrochloride	859-18-7	212-726-7	Xi;R43	Skin Sens.1 (H317)	30 - 50
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	Not Listed	*
Magnesium Stearate	557-04-0	209-150-3	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Lactose Monohydrate	64044-51-5	Not Listed	Not Listed	Not Listed	*
Gelatin	9000-70-8	232-554-6	Not Listed	Not Listed	*

**Additional Information:** \* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

- Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
- Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention. Delayed effects may occur. For information on potential delayed effects, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
- Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed**

## SAFETY DATA SHEET

Material Name: Lincomycin Hydrochloride Capsules  
Revision date: 06-Nov-2014

Page 3 of 9  
Version: 3.0

<b>Symptoms and Effects of Exposure:</b>	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
<b>Medical Conditions Aggravated by Exposure:</b>	None known

### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** Epinephrine and supportive measures are recommended if the patient presents with anaphylactic symptoms.

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO<sub>2</sub>, extinguishing powder, foam, or water.

### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

**Specific end use(s):** Pharmaceutical drug product

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Control Parameters

## SAFETY DATA SHEET

Material Name: Lincomycin Hydrochloride Capsules  
Revision date: 06-Nov-2014

Page 4 of 9  
Version: 3.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Lincomycin Hydrochloride  
Pfizer OEL TWA-8 Hr:

100 µg/m<sup>3</sup>

Talc (non-asbestiform)

ACGIH Threshold Limit Value (TWA)

2 mg/m<sup>3</sup>

Australia TWA

2.5 mg/m<sup>3</sup>

Austria OEL - MAKs

2 mg/m<sup>3</sup>

Belgium OEL - TWA

2 mg/m<sup>3</sup>

Bulgaria OEL - TWA

1.0 fiber/cm<sup>3</sup>

6.0 mg/m<sup>3</sup>

3.0 mg/m<sup>3</sup>

Czech Republic OEL - TWA

2.0 mg/m<sup>3</sup>

Denmark OEL - TWA

0.3 fiber/cm<sup>3</sup>

Finland OEL - TWA

0.5 fiber/cm<sup>3</sup>

Greece OEL - TWA

10 mg/m<sup>3</sup>

2 mg/m<sup>3</sup>

Hungary OEL - TWA

2 mg/m<sup>3</sup>

Ireland OEL - TWAs

10 mg/m<sup>3</sup>

0.8 mg/m<sup>3</sup>

Lithuania OEL - TWA

2 mg/m<sup>3</sup>

1 mg/m<sup>3</sup>

Netherlands OEL - TWA

0.25 mg/m<sup>3</sup>

OSHA - Final PELs - Table Z-3 Mineral D:

20 mppcf

Poland OEL - TWA

4.0 mg/m<sup>3</sup>

1.0 mg/m<sup>3</sup>

Portugal OEL - TWA

2 mg/m<sup>3</sup>

Romania OEL - TWA

2 mg/m<sup>3</sup>

Slovakia OEL - TWA

2 mg/m<sup>3</sup>

10 mg/m<sup>3</sup>

Slovenia OEL - TWA

2 mg/m<sup>3</sup>

Spain OEL - TWA

2 mg/m<sup>3</sup>

Sweden OEL - TWAs

2 mg/m<sup>3</sup>

1 mg/m<sup>3</sup>

Switzerland OEL -TWAs

2 mg/m<sup>3</sup>

Magnesium Stearate

ACGIH Threshold Limit Value (TWA)

10 mg/m<sup>3</sup>

Lithuania OEL - TWA

5 mg/m<sup>3</sup>

Sweden OEL - TWAs

5 mg/m<sup>3</sup>

The exposure limit(s) listed for solid components are only relevant if dust may be generated. Refer to available public information for specific member state Occupational Exposure Limits.

#### Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

## SAFETY DATA SHEET

Material Name: Lincomycin Hydrochloride Capsules  
Revision date: 06-Nov-2014

Page 5 of 9  
Version: 3.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Capsule	<b>Color:</b>	Blue
<b>Odor:</b>	No data available.	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture

**Solvent Solubility:** No data available  
**Water Solubility:** No data available  
**pH:** No data available.  
**Melting/Freezing Point (°C):** No data available  
**Boiling Point (°C):** No data available.

**Partition Coefficient: (Method, pH, Endpoint, Value)**

**Magnesium Stearate**

No data available

**Talc (non-asbestiform)**

No data available

**Gelatin**

No data available

**Lactose Monohydrate**

No data available

**Lincomycin Hydrochloride**

Measured 6-8 Log D 2.55

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):** No data available

**Flammability (Solids):** No data available

**Flash Point (Liquid) (°C):** No data available

**Upper Explosive Limits (Liquid) (% by Vol.):** No data available

**Lower Explosive Limits (Liquid) (% by Vol.):** No data available

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available  
**Chemical Stability:** Stable under normal conditions of use.

**Possibility of Hazardous Reactions**

**Oxidizing Properties:** No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

**Hazardous Decomposition Products:** No data available

## SAFETY DATA SHEET

Material Name: Lincomycin Hydrochloride Capsules  
Revision date: 06-Nov-2014

Page 6 of 9  
Version: 3.0

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

##### General Information:

The information included in this section describes the potential hazards of the individual ingredients.

##### Short Term:

Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions.

##### Known Clinical Effects:

The most common adverse effects reported with clinical use were diarrhea, nausea, rash, and vomiting. Effects on blood and blood-forming organs have also occurred. This compound can cross the placenta in pregnant women. Secreted in human breast milk.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

##### Lactose Monohydrate

Rat Oral LD 50 29700 mg/kg

##### Lincomycin Hydrochloride

Rat Oral LD 50 > 4000 mg/kg

Rat Para-periosteal LD 50 342mg/kg

Mouse Intravenous LD 50 214mg/kg

Rat Subcutaneous LD 50 9778mg/kg

##### Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

##### Lincomycin Hydrochloride

30 Day(s) Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose

30 Day(s) Rat Subcutaneous 60 mg/kg/day NOAEL None identified

3 Month(s) Rat Oral 300 mg/kg/day NOAEL None identified

3 Month(s) Dog Oral 400 mg/kg/day LOAEL None identified

6 Month(s) Dog Oral 100 mg/kg/day NOAEL Immune system

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### Lincomycin Hydrochloride

2 Generation Reproductive Toxicity Rat Oral 100 mg/kg LOAEL Fetotoxicity

Prenatal & Postnatal Development Rat Oral 100 mg/kg NOEL Not Teratogenic

Fertility and Embryonic Development Rat Subcutaneous 75 mg/kg/day NOAEL No effects at maximum dose

Embryo / Fetal Development Rat Subcutaneous 300 mg/kg/day NOAEL Not Teratogenic

Peri-/Postnatal Development Rat Subcutaneous 30 mg/kg/day NOAEL No effects at maximum dose

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Lactose Monohydrate

*In Vitro* Bacterial Mutagenicity (Ames) Negative

## SAFETY DATA SHEET

Material Name: Lincomycin Hydrochloride Capsules  
Revision date: 06-Nov-2014

Page 7 of 9  
Version: 3.0

### 11. TOXICOLOGICAL INFORMATION

#### Lincomycin Hydrochloride

Bacterial Mutagenicity (Ames) *Salmonella* Negative  
Mammalian Cell Mutagenicity Mouse Lymphoma Negative  
*In Vivo* Micronucleus Rat Negative  
Direct DNA Interaction Human Lymphocytes Negative

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

#### Talc (non-asbestiform)

**IARC:** Group 3 (Not Classifiable)

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided. See aquatic toxicity data for individual components below:

#### Toxicity:

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

#### Lincomycin Hydrochloride

<i>Lepomis macrochirus</i> (Bluegill Sunfish)	ASTM	LC50	96 Hours	>980 mg/L
<i>Daphnia magna</i> (Water Flea)	ASTM	EC50	48 Hours	>900 mg/L
<i>Anabaena flos-aquae</i> (Cyanobacteria)	OECD	EC50	72 Hours	0.03 mg/L
<i>Salmo gairdneri</i> (Trout)	ASTM	LC50	96 Hours	>980 mg/L

**Aquatic Toxicity Comments:** A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

**Persistence and Degradability:** No data available

#### Bio-accumulative Potential:

#### **Partition Coefficient: (Method, pH, Endpoint, Value)**

#### Lincomycin Hydrochloride

Measured 6-8 Log D 2.55

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## SAFETY DATA SHEET

Material Name: Lincomycin Hydrochloride Capsules  
Revision date: 06-Nov-2014

Page 8 of 9  
Version: 3.0

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision B



#### Lincomycin Hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	212-726-7

#### Talc (non-asbestiform)

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	238-877-9

#### Lactose Monohydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	Not Listed

#### Gelatin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-554-6



## SAFETY DATA SHEET

Material Name: Lincomycin Hydrochloride Capsules  
Revision date: 06-Nov-2014

Page 9 of 9  
Version: 3.0

### 15. REGULATORY INFORMATION

#### Magnesium Stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

### 16. OTHER INFORMATION

#### Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Xi - Irritant

R43 - May cause sensitization by skin contact.

**Data Sources:** Safety data sheets for individual ingredients. Publicly available toxicity information.

**Reasons for Revision:** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

**Revision date:** 06-Nov-2014

**Prepared by:** Product Stewardship Hazard Communication  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**